Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3129126 | 0.89 | SCN4A (0.57) | KMOSCN4A | |
| SCHEMBL3131639 | 0.87 | SCN4A (0.50) | KMOSCN4A | |
| SCHEMBL3126799 | 0.86 | KMO (0.60) | KMO | |
| SCHEMBL3125866 | 0.85 | KMO (0.58) | KMO | |
| SCHEMBL3133858 | 0.82 | SCN9A (0.53) | KMOSCN4A | |
| Formamide SCHEMBL27586309 | 0.81 | KMO (0.53) | KMOSCN4A | |
| SCHEMBL3131607 | 0.78 | SCN9A (0.59) | KMOSCN4A | |
| SCHEMBL3131946 | 0.78 | SCN9A (0.59) | KMO | |
| Dimethylformamide SCHEMBL27566652 | 0.78 | KMO (0.50) | KMOSCN4A | |
| Hydrochloric Acid SCHEMBL27566716 | 0.77 | KMO (0.49) | KMOSCN4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6867210-B2 | Aryl substituted pyrimidines | EURO-CELTIQUE S.A. (LU) | 2005-03-15 | — | — | US | disclosed |
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | EURO-CELTIQUE S.A. (LU) | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043305-A1 | Aryl substituted pyridines, pyrimidines, pyrazines and triazines and the use thereof | CACNA1S, CACNA1C, KYNU | KMO 661/4885SCN4A 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.